Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers
Abstract Background Systemic bevacizumab is a novel targeted anti-angiogenic therapy for high-output cardiac failure (HOCF) in hereditary hemorrhagic telangiectasia (HHT) but published data is limited. This survey-based study measured physician-reported safety, effectiveness and current treatment pr...
Main Authors: | Hanny Al-Samkari, Hasan A. Albitar, Scott E. Olitsky, Marianne S. Clancy, Vivek N. Iyer |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-019-1239-6 |
Similar Items
-
HEREDITARY HEMORRHAGIC TELANGIECTASIA
by: Messody Zagury, et al.
Published: (2015-03-01) -
Ocular lesions in hereditary hemorrhagic telangiectasia: genetics and clinical characteristics
by: Inés Gómez-Acebo, et al.
Published: (2020-06-01) -
Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era
by: Jamie eMcDonald, et al.
Published: (2015-01-01) -
TELANGIECTASIA HEMORRAGICA HEREDITARIA: A PROPOSITO DE DOS CASOS Hereditary hemorrhagic telangiectasias: A report of two cases
by: Mildrey Jiménez López, et al.
Published: (2009-03-01) -
Bevacizumab for Refractory Gastrointestinal Bleeding in Rendu-Osler-Weber Disease
by: Carlos Bernardes, et al.
Published: (2017-10-01)